Ser696
Javascript is not enabled on this browser. This site will not work properly without Javascript.
PhosphoSitePlus Homepage PhosphoSitePlus® v6.5.9.1
Powered by Cell Signaling Technology
Home > Phosphorylation Site Page: > Ser696  -  Tau (mouse)

Site Information
PVVsGDtsPRHLsNV   SwissProt Entrez-Gene
Blast this site against: NCBI  SwissProt  PDB 
Site Group ID: 449082

In vivo Characterization
Methods used to characterize site in vivo:
immunoassay ( 20 , 66 ) , immunoprecipitation ( 2 ) , mass spectrometry ( 3 , 9 , 10 , 11 , 12 , 13 , 14 , 15 , 16 , 17 , 18 , 21 , 22 , 23 , 24 , 25 , 26 , 27 , 28 , 29 , 30 , 31 , 32 , 33 , 34 , 35 , 36 , 37 , 38 , 39 , 40 , 41 , 42 , 43 , 44 , 45 , 46 , 47 , 48 , 49 , 50 , 52 , 53 , 57 , 58 , 59 , 60 , 61 , 62 , 64 , 69 , 70 ) , microscopy-colocalization with upstream kinase ( 73 ) , mutation of modification site ( 2 ) , phospho-antibody ( 2 , 4 , 6 , 7 , 8 , 20 , 51 , 54 , 55 , 56 , 63 , 65 , 66 , 67 , 68 , 71 , 72 , 73 ) , western blotting ( 2 , 4 , 6 , 7 , 20 , 51 , 55 , 56 , 63 , 65 , 66 , 67 , 68 , 72 , 73 )
Disease tissue studied:
Alzheimer's disease ( 6 , 8 , 73 ) , anthrax infection ( 18 ) , brain cancer ( 14 , 15 , 16 , 17 ) , neuroblastoma ( 2 , 68 ) , neuroendocrine cancer ( 14 , 15 , 16 , 17 )
Relevant cell line - cell type - tissue:
'brain, cerebellum' ( 11 , 67 , 72 ) , 'brain, cerebral cortex' ( 27 , 65 , 66 ) , 'brain, cerebrum' ( 67 , 72 ) , 'brain, embryonic' ( 25 , 28 , 31 , 32 , 33 , 35 , 38 , 39 , 44 , 45 , 47 , 53 , 58 , 59 , 60 , 61 , 73 ) , 'brain, forebrain' ( 50 ) , 'brain, hippocampus' ( 63 , 66 , 73 ) , 'brain, hippocampus' [APP (human), transgenic] ( 6 ) , 'brain, striatum' ( 20 ) , 'fat, brown' ( 21 ) , 'neuron, hippocampal'-brain ( 54 ) , 293 (epithelial) ( 2 ) , brain ( 4 , 12 , 13 , 14 , 15 , 16 , 17 , 21 , 22 , 23 , 24 , 30 , 34 , 36 , 37 , 40 , 41 , 42 , 43 , 46 , 51 , 52 , 55 , 56 , 62 , 70 , 71 , 73 ) , brain [CDK5R1 (mouse)] ( 55 ) , heart ( 10 , 21 , 29 , 48 ) , kidney ( 21 ) , liver ( 9 , 21 , 49 , 64 ) , lung ( 21 ) , mpkCCD (renal) ( 26 ) , Neuro-2a (neuron) ( 68 ) , neuron ( 7 ) , neuron-'brain, cerebral cortex' ( 8 ) , neuron-'brain, hippocampus' ( 2 ) , neuron:postsynaptic density-'brain, hippocampus, CA1 region' ( 3 ) , neuron:synaptosome-'brain, forebrain' ( 69 ) , P19 (testicular) ( 57 ) , pancreas ( 21 ) , SH-SY5Y (neural crest) ( 2 ) , spleen ( 18 , 21 ) , testis ( 21 )

Upstream Regulation
Regulatory protein:
Akt1 (mouse) ( 56 ) , APP (human) ( 65 ) , APP (mouse) ( 5 ) , CAMKK2 (mouse) ( 19 ) , CDK5R1 (mouse) ( 55 ) , DVL1 (mouse) ( 68 ) , GSK3B (mouse) ( 56 ) , NPC1 (mouse) ( 67 , 72 ) , PAR1 (mouse) ( 56 ) , PSEN1 (mouse) ( 5 ) , SERPINA3 (human) ( 65 ) , SNCA (mouse) ( 20 )
Putative in vivo kinases:
GSK3B (mouse) ( 20 )
Treatments:
anti-tau_antibody_ ( 8 ) , antichymotrypsin ( 65 ) , aroused animals ( 51 ) , beta-amyloid_42 ( 2 , 19 ) , cold_water_stress ( 63 ) , DI-PHPB ( 5 ) , donepezil ( 6 ) , ether ( 63 ) , fasting ( 66 ) , food deprivation ( 63 ) , glucose_starvation ( 71 ) , hibernating ( 51 ) , lithium ( 54 ) , long-term_potentiation ( 3 ) , MDMA ( 54 ) , refeeding ( 66 ) , seliciclib ( 54 ) , summer-active ( 51 ) , wortmannin ( 68 ) , xanthoceraside ( 6 )

Downstream Regulation
Effects of modification on Tau:
molecular association, regulation ( 20 ) , phosphorylation ( 2 ) , protein conformation ( 20 )
Induce interaction with:
SNCA (mouse) ( 20 )

Disease / Diagnostics Relevance
Relevant diseases:
Parkinson's disease ( 4 , 20 )

References 

1

Sacco F, et al. (2016) Glucose-regulated and drug-perturbed phosphoproteome reveals molecular mechanisms controlling insulin secretion. Nat Commun 7, 13250
27841257   Curated Info

2

Kam TI, et al. (2016) FcγRIIb-SHIP2 axis links Aβ to tau pathology by disrupting phosphoinositide metabolism in Alzheimer's disease model. Elife 5
27834631   Curated Info

3

Li J, et al. (2016) Long-term potentiation modulates synaptic phosphorylation networks and reshapes the structure of the postsynaptic interactome. Sci Signal 9, rs8
27507650   Curated Info

4

Credle JJ, et al. (2015) GSK-3β dysregulation contributes to parkinson's-like pathophysiology with associated region-specific phosphorylation and accumulation of tau and α-synuclein. Cell Death Differ 22, 838-51
25394490   Curated Info

5

Peng Y, et al. (2014) Potassium 2-(1-Hydroxypentyl)-Benzoate Improves Memory Deficits and Attenuates Amyloid and τ Pathologies in a Mouse Model of Alzheimer's Disease. J Pharmacol Exp Ther 350, 361-74
24893984   Curated Info

6

Jin G, et al. (2014) Xanthoceraside rescues learning and memory deficits through attenuating beta-amyloid deposition and tau hyperphosphorylation in APP mice. Neurosci Lett 573, 58-63
24810883   Curated Info

7

Congdon EE, Gu J, Sait HB, Sigurdsson EM (2013) Antibody Uptake into Neurons Occurs Primarily via Clathrin-dependent Fcγ Receptor Endocytosis and Is a Prerequisite for Acute Tau Protein Clearance. J Biol Chem 288, 35452-65
24163366   Curated Info

8

Yanamandra K, et al. (2013) Anti-tau antibodies that block tau aggregate seeding in vitro markedly decrease pathology and improve cognition in vivo. Neuron 80, 402-14
24075978   Curated Info

9

Wilson-Grady JT, Haas W, Gygi SP (2013) Quantitative comparison of the fasted and re-fed mouse liver phosphoproteomes using lower pH reductive dimethylation. Methods 61, 277-86
23567750   Curated Info

10

Lundby A, et al. (2013) In vivo phosphoproteomics analysis reveals the cardiac targets of β-adrenergic receptor signaling. Sci Signal 6, rs11
23737553   Curated Info

11

Schindler J, Ye J, Jensen ON, Nothwang HG (2013) Monitoring the native phosphorylation state of plasma membrane proteins from a single mouse cerebellum. J Neurosci Methods 213, 153-64
23246975   Curated Info

12

Trinidad JC, et al. (2012) Global identification and characterization of both O-GlcNAcylation and phosphorylation at the murine synapse. Mol Cell Proteomics 11, 215-29
22645316   Curated Info

13

Goswami T, et al. (2012) Comparative phosphoproteomic analysis of neonatal and adult murine brain. Proteomics 12, 2185-9
22807455   Curated Info

14

Guo A (2011) CST Curation Set: 12732; Year: 2011; Biosample/Treatment: tissue, brain/untreated; Disease: brain cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[ST]P Antibodies Used to Purify Peptides prior to LCMS: Phospho-(Ser) CDKs Substrate Antibody Cat#: 2324, PTMScan(R) Phospho-CDK Substrate Motif (K/RS*PXK/R) Immunoaffinity Beads Cat#: 1981
Curated Info

15

Guo A (2011) CST Curation Set: 12734; Year: 2011; Biosample/Treatment: tissue, brain/untreated; Disease: brain cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[ST]P Antibodies Used to Purify Peptides prior to LCMS: Phospho-(Ser) CDKs Substrate Antibody Cat#: 2324, PTMScan(R) Phospho-CDK Substrate Motif (K/RS*PXK/R) Immunoaffinity Beads Cat#: 1981
Curated Info

16

Guo A (2011) CST Curation Set: 12735; Year: 2011; Biosample/Treatment: tissue, brain/untreated; Disease: brain cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[ST]P Antibodies Used to Purify Peptides prior to LCMS: Phospho-(Ser) CDKs Substrate Antibody Cat#: 2324, PTMScan(R) Phospho-CDK Substrate Motif (K/RS*PXK/R) Immunoaffinity Beads Cat#: 1981
Curated Info

17

Guo A (2011) CST Curation Set: 12737; Year: 2011; Biosample/Treatment: tissue, brain/untreated; Disease: brain cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: PXpSP, pSPX(K/R) Antibodies Used to Purify Peptides prior to LCMS: Phospho-MAPK/CDK Substrates (PXSP or SPXR/K) (34B2) Rabbit mAb Cat#: 2325, PTMScan(R) Phospho-MAPK/CDK Substrate Motif (PXS*P, S*PXK/R) Immunoaffinity Beads Cat#: 1982
Curated Info

18

Manes NP, et al. (2011) Discovery of mouse spleen signaling responses to anthrax using label-free quantitative phosphoproteomics via mass spectrometry. Mol Cell Proteomics 10, M110.000927
21189417   Curated Info

19

Thornton C, et al. (2011) AMP-activated protein kinase (AMPK) is a tau kinase, activated in response to amyloid β-peptide exposure. Biochem J 434, 503-12
21204788   Curated Info

20

Wills J, et al. (2011) Tauopathic changes in the striatum of A53T α-synuclein mutant mouse model of Parkinson's disease. PLoS One 6, e17953
21445308   Curated Info

21

Huttlin EL, et al. (2010) A tissue-specific atlas of mouse protein phosphorylation and expression. Cell 143, 1174-89
21183079   Curated Info

22

Possemato A (2010) CST Curation Set: 9879; Year: 2010; Biosample/Treatment: tissue, brain/untreated; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[ST]XP Antibodies Used to Purify Peptides prior to LCMS: Phospho-(Ser) 14-3-3 Binding Motif (4E2) Mouse mAb Cat#: 9606
Curated Info

23

Possemato A (2010) CST Curation Set: 9878; Year: 2010; Biosample/Treatment: tissue, brain/untreated; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[ST]XP Antibodies Used to Purify Peptides prior to LCMS: Phospho-(Ser) 14-3-3 Binding Motif (4E2) Mouse mAb Cat#: 9606
Curated Info

24

Wiśniewski JR, et al. (2010) Brain phosphoproteome obtained by a FASP-based method reveals plasma membrane protein topology. J Proteome Res 9, 3280-9
20415495   Curated Info

25

Zhou J (2010) CST Curation Set: 9272; Year: 2010; Biosample/Treatment: tissue, brain/untreated; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: (F/Y)XpS
Curated Info

26

Rinschen MM, et al. (2010) Quantitative phosphoproteomic analysis reveals vasopressin V2-receptor-dependent signaling pathways in renal collecting duct cells. Proc Natl Acad Sci U S A 107, 3882-7
20139300   Curated Info

27

Tweedie-Cullen RY, Reck JM, Mansuy IM (2009) Comprehensive mapping of post-translational modifications on synaptic, nuclear, and histone proteins in the adult mouse brain. J Proteome Res 8, 4966-82
19737024   Curated Info

28

Zhou J (2009) CST Curation Set: 7440; Year: 2009; Biosample/Treatment: tissue, brain/untreated; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[ST]P
Curated Info

29

Zhou J (2009) CST Curation Set: 7432; Year: 2009; Biosample/Treatment: tissue, heart/untreated; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pSP
Curated Info

30

Zhou J (2009) CST Curation Set: 7431; Year: 2009; Biosample/Treatment: tissue, brain/untreated; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pSP
Curated Info

31

Zhou J (2009) CST Curation Set: 7428; Year: 2009; Biosample/Treatment: tissue, brain/untreated; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pSP
Curated Info

32

Zhou J (2009) CST Curation Set: 7429; Year: 2009; Biosample/Treatment: tissue, brain/untreated; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pSP
Curated Info

33

Zhou J (2009) CST Curation Set: 7412; Year: 2009; Biosample/Treatment: tissue, brain/untreated; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: HXXp[ST]
Curated Info

34

Zhou J (2009) CST Curation Set: 7384; Year: 2009; Biosample/Treatment: tissue, brain/untreated; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: QXp[ST]
Curated Info

35

Zhou J (2009) CST Curation Set: 7382; Year: 2009; Biosample/Treatment: tissue, brain/untreated; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: QXp[ST]
Curated Info

36

Zhou J (2009) CST Curation Set: 7375; Year: 2009; Biosample/Treatment: tissue, brain/untreated; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: YXp[ST]
Curated Info

37

Zhou J (2009) CST Curation Set: 7376; Year: 2009; Biosample/Treatment: tissue, brain/untreated; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: YXp[ST]
Curated Info

38

Zhou J (2009) CST Curation Set: 7373; Year: 2009; Biosample/Treatment: tissue, brain/untreated; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: YXp[ST]
Curated Info

39

Zhou J (2009) CST Curation Set: 7374; Year: 2009; Biosample/Treatment: tissue, brain/untreated; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: YXp[ST]
Curated Info

40

Guo A (2008) CST Curation Set: 5004; Year: 2008; Biosample/Treatment: tissue, brain/untreated; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[ST]P Antibodies Used to Purify Peptides prior to LCMS: Phospho-(Ser) CDKs Substrate Antibody Cat#: 2324, PTMScan(R) Phospho-CDK Substrate Motif (K/RS*PXK/R) Immunoaffinity Beads Cat#: 1981
Curated Info

41

Guo A (2008) CST Curation Set: 5005; Year: 2008; Biosample/Treatment: tissue, brain/untreated; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[ST]P Antibodies Used to Purify Peptides prior to LCMS: Phospho-(Ser) CDKs Substrate Antibody Cat#: 2324, PTMScan(R) Phospho-CDK Substrate Motif (K/RS*PXK/R) Immunoaffinity Beads Cat#: 1981
Curated Info

42

Guo A (2008) CST Curation Set: 5006; Year: 2008; Biosample/Treatment: tissue, brain/untreated; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[ST]P Antibodies Used to Purify Peptides prior to LCMS: Phospho-(Ser) CDKs Substrate Antibody Cat#: 2324, PTMScan(R) Phospho-CDK Substrate Motif (K/RS*PXK/R) Immunoaffinity Beads Cat#: 1981
Curated Info

43

Guo A (2008) CST Curation Set: 5007; Year: 2008; Biosample/Treatment: tissue, brain/untreated; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[ST]P Antibodies Used to Purify Peptides prior to LCMS: Phospho-(Ser) CDKs Substrate Antibody Cat#: 2324, PTMScan(R) Phospho-CDK Substrate Motif (K/RS*PXK/R) Immunoaffinity Beads Cat#: 1981
Curated Info

44

Zhou J (2008) CST Curation Set: 4864; Year: 2008; Biosample/Treatment: tissue, brain/untreated; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[ST]P Antibodies Used to Purify Peptides prior to LCMS: Phospho-Thr-Pro Motif Antibody (polyAB) Cat#: 3003, PTMScan(R) Phospho-Thr-Pro Motif (T*P) Immunoaffinity Beads Cat#: 1996
Curated Info

45

Zhou J (2008) CST Curation Set: 4860; Year: 2008; Biosample/Treatment: tissue, brain/untreated; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[ST]P
Curated Info

46

Zhou J (2008) CST Curation Set: 4784; Year: 2008; Biosample/Treatment: tissue, brain/untreated; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[ST]P Antibodies Used to Purify Peptides prior to LCMS: Phospho-(Ser) CDKs Substrate Antibody Cat#: 2324, PTMScan(R) Phospho-CDK Substrate Motif (K/RS*PXK/R) Immunoaffinity Beads Cat#: 1981
Curated Info

47

Zhou J (2008) CST Curation Set: 4785; Year: 2008; Biosample/Treatment: tissue, brain/untreated; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[ST]P Antibodies Used to Purify Peptides prior to LCMS: Phospho-(Ser) CDKs Substrate Antibody Cat#: 2324, PTMScan(R) Phospho-CDK Substrate Motif (K/RS*PXK/R) Immunoaffinity Beads Cat#: 1981
Curated Info

48

Zhou J (2008) CST Curation Set: 4786; Year: 2008; Biosample/Treatment: tissue, heart/untreated; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[ST]P Antibodies Used to Purify Peptides prior to LCMS: Phospho-(Ser) CDKs Substrate Antibody Cat#: 2324, PTMScan(R) Phospho-CDK Substrate Motif (K/RS*PXK/R) Immunoaffinity Beads Cat#: 1981
Curated Info

49

Zhou J (2008) CST Curation Set: 4787; Year: 2008; Biosample/Treatment: tissue, liver/untreated; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[ST]P Antibodies Used to Purify Peptides prior to LCMS: Phospho-(Ser) CDKs Substrate Antibody Cat#: 2324, PTMScan(R) Phospho-CDK Substrate Motif (K/RS*PXK/R) Immunoaffinity Beads Cat#: 1981
Curated Info

50

Collins MO, et al. (2008) Phosphoproteomic analysis of the mouse brain cytosol reveals a predominance of protein phosphorylation in regions of intrinsic sequence disorder. Mol Cell Proteomics 7, 1331-48
18388127   Curated Info

51

Su B, et al. (2008) Physiological regulation of tau phosphorylation during hibernation. J Neurochem 105, 2098-108
18284615   Curated Info

52

Zhou J (2008) CST Curation Set: 4338; Year: 2008; Biosample/Treatment: tissue, brain/untreated; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pSP
Curated Info

53

Zhou J (2008) CST Curation Set: 4339; Year: 2008; Biosample/Treatment: tissue, brain/untreated; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pSP
Curated Info

54

Busceti CL, et al. (2008) Enhanced tau phosphorylation in the hippocampus of mice treated with 3,4-methylenedioxymethamphetamine ("Ecstasy"). J Neurosci 28, 3234-45
18354027   Curated Info

55

Wen Y, et al. (2008) Interplay between cyclin-dependent kinase 5 and glycogen synthase kinase 3 beta mediated by neuregulin signaling leads to differential effects on tau phosphorylation and amyloid precursor protein processing. J Neurosci 28, 2624-32
18322105   Curated Info

56

Dickey CA, et al. (2008) Akt and CHIP coregulate tau degradation through coordinated interactions. Proc Natl Acad Sci U S A 105, 3622-7
18292230   Curated Info

57

Smith JC, et al. (2007) A differential phosphoproteomic analysis of retinoic acid-treated P19 cells. J Proteome Res 6, 3174-86
17622165   Curated Info

58

Guo A (2007) CST Curation Set: 2715; Year: 2007; Biosample/Treatment: tissue, brain/-; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: PXpSP, pSPX(K/R) Antibodies Used to Purify Peptides prior to LCMS: Phospho-MAPK/CDK Substrates (PXSP or SPXR/K) (34B2) Rabbit mAb Cat#: 2325, PTMScan(R) Phospho-MAPK/CDK Substrate Motif (PXS*P, S*PXK/R) Immunoaffinity Beads Cat#: 1982
Curated Info

59

Guo A (2007) CST Curation Set: 2717; Year: 2007; Biosample/Treatment: tissue, brain/-; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[ST](D/E)X(D/E)
Curated Info

60

Guo A (2007) CST Curation Set: 2672; Year: 2007; Biosample/Treatment: tissue, brain/-; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

61

Guo A (2007) CST Curation Set: 2677; Year: 2007; Biosample/Treatment: tissue, brain/-; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[ST]Q Antibodies Used to Purify Peptides prior to LCMS: Phospho-(Ser/Thr) ATM/ATR Substrate Antibody Cat#: 2851
Curated Info

62

Guo A (2007) CST Curation Set: 2682; Year: 2007; Biosample/Treatment: tissue, brain/-; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[ST]Q Antibodies Used to Purify Peptides prior to LCMS: Phospho-(Ser/Thr) ATM/ATR Substrate Antibody Cat#: 2851
Curated Info

63

Ikeda Y, Ishiguro K, Fujita SC (2007) Ether stress-induced Alzheimer-like tau phosphorylation in the normal mouse brain. FEBS Lett 581, 891-7
17289030   Curated Info

64

Villén J, Beausoleil SA, Gerber SA, Gygi SP (2007) Large-scale phosphorylation analysis of mouse liver. Proc Natl Acad Sci U S A 104, 1488-93
17242355   Curated Info

65

Padmanabhan J, Levy M, Dickson DW, Potter H (2006) Alpha1-antichymotrypsin, an inflammatory protein overexpressed in Alzheimer's disease brain, induces tau phosphorylation in neurons. Brain 129, 3020-34
16987932   Curated Info

66

Li X, Lu F, Wang JZ, Gong CX (2006) Concurrent alterations of O-GlcNAcylation and phosphorylation of tau in mouse brains during fasting. Eur J Neurosci 23, 2078-86
16630055   Curated Info

67

Yu W, Ko M, Yanagisawa K, Michikawa M (2005) Neurodegeneration in heterozygous Niemann-Pick type C1 (NPC1) mouse: implication of heterozygous NPC1 mutations being a risk for tauopathy. J Biol Chem 280, 27296-302
15919659   Curated Info

68

Wang HH, et al. (2005) Overexpression of dishevelled-1 attenuates wortmannin-induced hyperphosphorylation of cytoskeletal proteins in N2a cell. Acta Pharmacol Sin 26, 679-84
15916733   Curated Info

69

Collins MO, et al. (2005) Proteomic analysis of in vivo phosphorylated synaptic proteins. J Biol Chem 280, 5972-82
15572359   Curated Info

70

Ballif BA, et al. (2004) Phosphoproteomic analysis of the developing mouse brain. Mol Cell Proteomics 3, 1093-101
15345747   Curated Info

71

Liu F, et al. (2004) O-GlcNAcylation regulates phosphorylation of tau: a mechanism involved in Alzheimer's disease. Proc Natl Acad Sci U S A 101, 10804-9
15249677   Curated Info

72

Sawamura N, et al. (2001) Site-specific phosphorylation of tau accompanied by activation of mitogen-activated protein kinase (MAPK) in brains of Niemann-Pick type C mice. J Biol Chem 276, 10314-9
11152466   Curated Info

73

Jicha GA, et al. (1999) cAMP-dependent protein kinase phosphorylations on tau in Alzheimer's disease. J Neurosci 19, 7486-94
10460255   Curated Info